Trial of Vaccine to Prevent Ovarian Cancer Recurrence Expands to Advanced-stage Patients

Trial of Vaccine to Prevent Ovarian Cancer Recurrence Expands to Advanced-stage Patients
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer. While the study initially aimed to enroll 80 patients, it is now recruiting 120 patients with platinum-sensitive advanced ovarian cancer (stage III and IV) who completed a single round of platinum-based chemotherapy. Previously, patients were required

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , , .

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Leave a Comment

Your email address will not be published. Required fields are marked *